Form 4: Cardio Diagnostics Director Receives Stock Options

Director Wendy J. Betts was granted 3,205 stock options in Cardio Diagnostics Holdings, Inc. as part of a routine equity compensation.

Summary

• Director Wendy J. Betts acquired 3,205 stock options in Cardio Diagnostics Holdings, Inc. (CDIO).
• The options have an exercise price of $1.95 per share.
• The grant date and exercisable date for these options is March 31, 2026.
• The options expire on March 31, 2036.
• Following this transaction, the director holds a total of 9,513 derivative securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of stock options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future market performance of CDIO common stock exceeding the $1.95 exercise price.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or financial performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the healthcare technology sector.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is consistent with standard practices for small-cap growth companies to preserve cash while incentivizing leadership.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Director may exercise options at any time prior to the expiration date of March 31, 2036.

Key Dates

Keywords

Cardio Diagnostics, CDIO, Director Compensation, Stock Options, Insider Transaction, Form 4